Biocept Launches Lung Cancer Offering
By launching blood-based biomarker testing for non-small cell lung cancer (NSCLC), along with the previously commercialized breast cancer offering,
The Company's first
"The evaluation of biomarker status is the standard-of-care in determining the course of therapy for patients with lung cancer," said
"A liquid biopsy, or blood based genomic test, has the advantage of being far less invasive than a surgical biopsy, therefore being appropriate for diagnostic and importantly, monitoring purposes. This gives physicians insight into the molecular status of the patient in real time so that therapeutic changes can be made for better patient outcomes," says
The Company currently plans to offer additional biomarkers for lung cancer that physicians use when making treatment decisions before the end of the year and during 2015, including EGFR mutations, Ros1 fusions, KRAS mutations, and EGFR and MET amplification. EGFR mutation status, like ALK, is a biomarker included in guidelines that oncologists follow to determine the best treatment plan for a patient. Patients who have EGFR mutations are eligible for Tyrosine Kinase Inhibitors such as TarcevaR from
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to cost savings, improvement of outcomes, our impact on diagnostic strategies and planned future
offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
1Lokhandwala T, Dann R, Johnson M, et al. Costs of the Diagnostic Workup for Lung Cancer - A Medicare Claims Analysis. Presented at: 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology;
CONTACT: Investor Contact:Source:The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com Media Contact:The Ruth Group Calvin Allen (646) 536-7002 callen@theruthgroup.com
News Provided by Acquire Media